An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
VERDICT
The label
Markup
read at $32.26
Merck KGaA holds its Markup at $32.26.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-27
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 19 days
Price
$32.26
Valuation
24.26 trailing · 15.40 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.83
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 6% discount to our $34.08 fair value, weak competitive moat.
Read at
$32.26
24.26 P/E · 15.40 fwd
Our fair value
$34.08
6% discount
Analyst target (avg)
$34.04
+6% to current
Target low $34.00Analyst target rangeTarget high $34.08
▲ current $32.26 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$32.26
you are here
Conservative
$34.08
+6%
Analyst avg
$34.04
+6%
Our fair value
$34.08
+6%
Analyst high
$34.08
+6%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-2.80%
Profit margin
12.08%
Debt to equity
40.37
Analyst consensus
None · 2 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 19.4% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 6.1% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 0.0% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Labs in Germany at a modest discount
Picture a Frankfurt lab bench where reagents and molecules quietly feed medicines sold from Sao Paulo to Shanghai. Merck KGaA sits behind that supply chain and the shares sit 9 percent below our fair value at a forward multiple of 14.9 times, with an ethical screen cleared and an opportunity rating attached.
Revenue dipped 3 percent lately, yet the 12 percent profit margin and 9 percent return on equity still deliver cash in a sector that rarely blows up overnight. The two-analyst consensus lines up with our fair value near 34 dollars, so the gap is narrow but real.
A weak moat leaves the business open to generics pressure and life-science rivals, and growth looks thin. Any slip in margins would close the safety cushion fast. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Germany and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
MKKGY trades on PNK (the company is based in Germany). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it strong buy, with a mean price target of $34. Entered 2026-07-18 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-18Markup$30.97+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (2 analysts) rates it strong buy, with a mean price target of $34.
2026-07-03Markup$30.97+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$30.97Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$26.54
+18.3%
·
$1,183
+18.3%
2 months
$25.71
+22.1%
$0.51
$1,241
+24.1%
3 months
$24.62
+27.5%
$0.51
$1,296
+29.6%
6 months
$27.57
+13.9%
$0.51
$1,157
+15.7%
1 year
$26.07
+20.4%
$0.51
$1,224
+22.4%
2 years
$35.82
-12.4%
$1.01
$905
-9.5%
3 years
$34.50
-9.0%
$1.48
$953
-4.7%
5 years
$34.84
-9.9%
$2.35
$969
-3.1%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever MKKGY does next, these words stay.
Merck KGaA · MKKGY · Markup · $32.26
Recorded 2026-07-27 · before the outcome · scored mechanically
